Click here to complete our survey for the Consensus Framework for the Optimal Delivery of Bispecific Antibodies for Multiple Myeloma: qualtrics.ucl.ac.uk/jfe/form/SV_0I… Thank you for your support! Rakesh Popat Dr Pinkie Chambers Andrea Preston UK Myeloma Society

Great to now have immunoglobulin prophylaxis available in England for bispecific antibodies in myeloma. Thanks for the hard work from the UK EMMBRAce team in pushing the case for this #mmsm ucl.ac.uk/lifesciences-f… NHS commissioning criteria👇

Myeloma Paper of the Day, April 3rd, suggested by Robert Orlowski (Robert Z. Orlowski) MD Anderson Cancer Center Sireesha Asoori Larissa Brunaldi Rakesh Popat Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Yi Lin oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews

The efficacy of all cell-based immunotherapies, including CAR-T cells, but also allogeneic stem cell transplantation, is constrained by the presence of a high tumor burden. ow.ly/v2S750VyEnP #immunobiologyandimmunotherapy

MHRA first to approve Bela Vd and Bela Pd for relapsed myeloma. UK myeloma docs: remember to enrol into the ProMMise trial of Bela-Vd so we can build the evidence to remove ocular examinations

Interesting set up for the myeloma oral abstract session BSH - Haematology

Nothing but amazing times across the pond with ⁦Gordon Cook⁩ ⁦Rakesh Popat⁩ and the entire ⁦Myeloma UK⁩ group !! Proving that we can all work together no matter which side of the road you drive on ❤️. #mmsm

Excellent session on frailty and myeloma BSH - Haematology. Inspiring, entertaining and practice changing talks delivered by Gordon Cook Annie Mac 🏳️‍🌈 and Salomon Mainer from IFM. Take home message: stop Dex early! #downwithdex #mmsm

Global Access to Multiple Myeloma Therapies by Rawan Atallah, MD & GLAMM team JCO Global Oncology USMIRC News OncoAlert LARVOL #USMIRC #mmsm #MedTwitter #MedEd #سرطان_الدم #المايلوما ascopubs.org/doi/10.1200/GO…

New high risk definition for myeloma is out! Time to start doing TP53 mutation for all myeloma cases. #IMWG ascopubs.org/doi/10.1200/JC…

Late breaking abstract 📢 Tec + Tal showing high response in EMD with strict central response assessments. Good to see dual antigen targeting making a difference in this high risk group. #mmsm #EHA2025

Kwee Yong from UCL Cancer Institute making the case we need to understand the biology of smouldering myeloma better to pick the right intervention. #EHA2025

Elran + DR for transplant ineligible myeloma patients. Impressive response rates with Q4W dosing of Elran. Looking forward to the treatment deescalation strategies in phase 3 #EHA2025

What’s up with Beta 2 microglobulin (B2M) and myeloma? Why is it the sole non-cytogenetic marker used in the new IMWG high risk definition? Why does it matter whether the creatinine is high or not? Thread 1/

NICE draft guidance to fund Belantamab Mafodotin plus bortezomib and dexamethasone for relapsed myeloma in England. But we need to evaluate less frequent dosing schedules. Our ProMMise trial is doing just that. #UKMRA Leeds CTRU #mmsm thelancet.com/journals/lanon…

A great resource with lots of practical guidance 👇

📢Final BELLINI results at 45.6 months follow-up show no overall survival benefit of venetoclax in the general relapsed or refractory multiple myeloma population. Post-hoc analyses suggest benefits are limited to biomarker-positive subgroups. 👇 shorturl.at/bwOYn

Elevation of BCMA cell surface expression via proteasome inhibition augments and restores anti-BCMA CAR T cell activity. Combine PI with anti-BCMA CAR-T? ashpublications.org/blood/article/…

📣 UK health care professionals! Join myself, Charlotte Pawlyn and Dean Smith tomorrow at 5pm BST to hear about how you can join us in the UKMRA ProMMise trial. Charlotte Pawlyn Dean Smith Leeds CTRU Details below 👇👇👇

Nice editorial👇 A new chapter in relapsed or refractory multiple myeloma - The Lancet Haematology thelancet.com/journals/lanha…